Current Report Filing (8-k)
March 02 2020 - 4:52PM
Edgar (US Regulatory)
false 0000012208 0000012208 2020-02-25 2020-02-25 0000012208 us-gaap:CommonStockMember 2020-02-25 2020-02-25 0000012208 us-gaap:CommonClassBMember 2020-02-25 2020-02-25
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report: February 25, 2020
(Date of earliest event reported)
BIO-RAD LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
Commission File Number: 1-7928
|
|
|
|
|
Delaware
|
|
94-1381833
|
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
1000 Alfred Nobel Dr.
Hercules, California 94547
(Address of principal executive offices, including zip code)
(510) 724-7000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
|
Class A Common Stock, Par Value $0.0001 per share
|
|
BIO
|
|
New York Stock Exchange
|
|
Class B Common Stock, Par Value $0.0001 per share
|
|
BIOb
|
|
New York Stock Exchange
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
ITEM 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On February 25, 2020, James R. Stark the Vice-President, Controller of Bio-Rad Laboratories, Inc. (the “Company”) and the Company’s principal accounting officer, notified the Company of his plans to retire from the Company, effective June 5, 2020. Mr. Stark’s retirement concludes thirty six years of service to the Company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
BIO-RAD LABORATORIES, INC.
|
|
|
|
|
|
|
|
|
|
Date: March 2, 2020
|
|
|
|
By:
|
|
/s/ Timothy S. Ernst
|
|
|
|
|
|
|
|
Timothy S. Ernst
|
|
|
|
|
|
|
|
Executive Vice President, General Counsel and Secretary
|
Bio Rad Laboratories (NYSE:BIO.B)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bio Rad Laboratories (NYSE:BIO.B)
Historical Stock Chart
From Apr 2023 to Apr 2024
